$198.80
1.32% yesterday
NYSE, Jun 27, 10:13 pm CET
ISIN
US2358511028
Symbol
DHR

Danaher Stock price

$198.80
+9.62 5.09% 1M
-32.30 13.98% 6M
-30.75 13.40% YTD
-52.96 21.04% 1Y
-28.48 12.53% 3Y
+46.00 30.11% 5Y
+141.86 249.17% 10Y
+181.25 1,032.70% 20Y
NYSE, Closing price Fri, Jun 27 2025
-2.66 1.32%
ISIN
US2358511028
Symbol
DHR
Sector

Key metrics

Basic
Market capitalization
$142.3b
Enterprise Value
$156.8b
Net debt
$14.5b
Cash
$2.0b
Shares outstanding
715.6m
Valuation (TTM | estimate)
P/E
38.08 | 25.56
P/S
5.97 | 5.75
EV/Sales
6.58 | 6.34
EV/FCF
31.98
P/B
2.80
Dividends
DPS
$1.08
Yield 1Y | 5Y
0.54% | 0.39%
Growth 1Y | 5Y
9.25% | 12.37%
Payout 1Y | 3Y
20.42% | 13.87%
Increased
11 Years
Financials (TTM | estimate)
Revenue
$23.8b | $24.7b
EBITDA
$7.5b | $7.7b
EBIT
$5.2b
Net Income
$3.8b | $5.6b
Free Cash Flow
$4.9b
Growth (TTM | estimate)
Revenue
0.35% | 3.56%
EBITDA
4.08% | 2.45%
EBIT
2.65%
Net Income
-14.47% | 42.74%
Free Cash Flow
-11.79%
Margin (TTM | estimate)
Gross
59.80%
EBITDA
31.56% | 31.33%
EBIT
21.67%
Net
15.81% | 22.51%
Free Cash Flow
20.58%
Financial Health
Equity Ratio
63.89%
Return on Equity
7.87%
ROCE
7.12%
ROIC
5.85%
Debt/Equity
0.32
More
EPS
$5.22
FCF per Share
$6.85
Short interest
1.22%
Employees
62.00k
Rev per Employee
$390.00k
Show more

Is Danaher a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

Danaher Stock Analysis

Unlock Scores for Free

Analyst Opinions

32 Analysts have issued a Danaher forecast:

28x Buy
88%
4x Hold
13%

Analyst Opinions

32 Analysts have issued a Danaher forecast:

Buy
88%
Hold
13%

Financial data from Danaher

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
23,820 23,820
0% 0%
100%
- Direct Costs 9,575 9,575
3% 3%
40%
14,245 14,245
3% 3%
60%
- Selling and Administrative Expenses 7,489 7,489
3% 3%
31%
- Research and Development Expense 1,595 1,595
6% 6%
7%
7,518 7,518
4% 4%
32%
- Depreciation and Amortization 2,357 2,357
7% 7%
10%
EBIT (Operating Income) EBIT 5,161 5,161
3% 3%
22%
Net Profit 3,765 3,765
14% 14%
16%

In millions USD.

Don't miss a Thing! We will send you all news about Danaher directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Danaher Stock News

Neutral
PRNewsWire
one day ago
WASHINGTON , June 27, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR), a leading global life sciences and diagnostics innovator, today announced that Martin Stumpe will be appointed Chief Technology and AI Officer, effective October 1, 2025. He will report directly to Rainer Blair, President and Chief Executive Officer.
Neutral
PRNewsWire
one day ago
WASHINGTON , June 27, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR), a leading global life sciences and diagnostics innovator, today announced that Greg Milosevich has been appointed by its Board of Directors to be Executive Vice President of Danaher with responsibility for its Life Sciences business, effective July 1, 2025. Mr. Milosevich has served as Vice President and Group Executive...
Positive
Seeking Alpha
9 days ago
The company has achieved returns on equity above 7.8% since 2019. Additionally, it reduced its liabilities-to-assets ratio to 35.72% this quarter, indicating a low risk of bankruptcy. Danaher expects an excellent growth outlook in the upcoming years, due to the significant investment that the biopharma industry has dedicated to developing new medical therapies. Between 2017 and 2024, Danaher in...
More Danaher News

Company Profile

Danaher Corp. operates as a medical company, which designs, manufactures, and markets professional, medical, industrial and commercial products and services. It operates through the following segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines. The Diagnostics segment comprises of analytical instruments, reagents, consumables, software, and services that hospitals, physician's offices, reference laboratories, and other critical care settings use to diagnose disease and make treatment decisions. The Environmental & Applied Solution segment offers products and services that help protect important resources and keep global food and water supplies safe. The company was founded by Steven M. Rales and Mitchell P. Rales in 1969 and is headquartered in Washington, DC.

Head office United States
CEO Rainer Blair
Employees 62,000
Founded 1984
Website www.danaher.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today